1[1]Chandraratna RA. Rational design of receptor-selective retinoids[J]. J Am Acad Dermatol, 1998, 39(4 Pt 2): S124-128.
2[2]Duvic M, Asano AT, Hager C, et al. The pathogenesis of psoriasis and the mechanism of action of tazarotene[J]. J Am Acad Dermatol, 1998, 39(4 Pt 2): S129-133.
3[3]Nagpal S, Patel S, Asano AT, et al. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin [J]. J Invest Dermatol, 1996, 106(2): 269-274.
3Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid[J]. Dermatologiea, 1978, 157(4): 238-244.
4Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents[J]. J Am Acad Dermatol, 2002, 46(1): 1-23.
5Cunliffe WJ, Berth-Jones J, Claudy A, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris[J]. J Am Acad Dermatol, 1992, 26(5 Pt 1): 736-743.
6Schmitt J,Wozel G.The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis[J].Dermatology,2005,210:194-199.
